Germany's Evotec beats FY 2025 revenue expectations

Evotec SE

10/03/2026 06:42

Overview

Germany life science firm's preliminary FY 2025 revenue beat analyst expectations

Adjusted EBITDA for FY 2025 within co's provided guidance range in the release

Company announced 'Horizon' transformation plan to streamline operations and enhance growth

Outlook

Evotec expects 2026 group revenues of €700 mln-€780 mln

Company anticipates 2026 group adjusted EBITDA of €0-40 mln

Evotec sees run-rate savings of ~€75 mln by end of 2027

Result Drivers

CENTERS OF EXCELLENCE - New Centers of Excellence will concentrate expertise and innovation to enhance competitiveness

Company press release: ID:nEQ62bTdga

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Group Revenue
Beat
EUR 788 mln
EUR 778.88 mln (8 Analysts)
FY Group Adjusted EBITDA
EUR 41 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Evotec SE is €9.70, about 84.1% above its March 9 closing price of €5.27

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)